Foghorn Therapeutics FHTX

$ 8.28 -0.3%

Quarterly report 2024-Q3
added 11-04-2024

Foghorn Therapeutics Income Statement 2011-2024 | FHTX

Annual Income Statement Foghorn Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	291 M	219 M	850 M	221 M	-	-	-	-	-	-	-	-	-
Shares	42 M	41.6 M	37.2 M	11 M	-	-	-	-	-	-	-	-	-
Historical Prices	6.94	5.27	22.9	20.3	-	-	-	-	-	-	-	-	-
Net Income	-98.4 M	-109 M	-101 M	-68.8 M	-51.1 M	-26.3 M	-	-	-	-	-	-	-
Revenue	34.2 M	19.2 M	1.32 M	430 K	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-108 M	-117 M	-101 M	-68.5 M	-51.1 M	-	-	-	-	-	-	-	-
Interest Expense	-	-	2.49 M	979 K	540 K	-	-	-	-	-	-	-	-
EBITDA	-104 M	-114 M	-97.5 M	-67.2 M	-50.4 M	-25.7 M	-	-	-	-	-	-	-
Operating Expenses	142 M	136 M	102 M	69 M	51.1 M	26 M	-	-	-	-	-	-	-
General and Administrative Expenses	32.4 M	30.7 M	21.7 M	11.2 M	6.72 M	4.82 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Foghorn Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	62.6 M	51.6 M	42.4 M	42.3 M	42 M	41.8 M	41.8 M	41.8 M	41.7 M	41.5 M	41.4 M	41.3 M	37 M	36.8 M	36.8 M	36.8 M	5.88 M	5.42 M	5.15 M	4.87 M	4.29 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-19.1 M	-23 M	-25 M	-	-14.3 M	-29.5 M	-30.5 M	-	-25.8 M	-27.3 M	-26.9 M	-	-26.1 M	-23.1 M	-23 M	-	-18.4 M	-15.7 M	-14 M	-	-51.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	7.81 M	6.89 M	5.05 M	-	17.5 M	5.6 M	5.31 M	-	6.63 M	4.49 M	3.92 M	-	41 K	279 K	286 K	-	179 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-23.9 M	-26.6 M	-28.2 M	-	-17.1 M	-32 M	-33.3 M	-	-28.3 M	-29.2 M	-27.8 M	-	-26.3 M	-23.3 M	-23.1 M	-	-18.5 M	-15.5 M	-13.7 M	-	-13.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	499 K	495 K	486 K	-	202 K	198 K	258 K	-	113 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-23.2 M	-25.8 M	-27.4 M	-	-16.2 M	-31.2 M	-32.5 M	-	-27.4 M	-28.4 M	-27 M	-	-25.5 M	-22.5 M	-22.4 M	-	-18.2 M	-15.3 M	-13.5 M	-	-12.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	31.7 M	33.5 M	33.2 M	-	34.6 M	37.6 M	38.6 M	-	34.9 M	33.7 M	31.7 M	-	26.3 M	23.5 M	23.4 M	-	18.7 M	15.5 M	13.7 M	-	13.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	6.97 M	7.32 M	7.71 M	-	8.31 M	8.4 M	8.64 M	-	7.96 M	7.7 M	7.22 M	-	5.81 M	4.9 M	4.69 M	-	2.56 M	1.91 M	2.22 M	-	1.81 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency